ADPT Quote, Financials, Valuation and Earnings

Regeneron Pharmaceuticals, Inc. has a net margin of 10.16% compared to Adaptive Biotechnologies Corp.'s net margin of 38.89%. Adaptive Biotechnologies Corp.'s return on equity of -39.8% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

Adaptive Biotechnologies Corp. has a consensus price target of $19.86, signalling upside risk potential of 18.55%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $788.28 which suggests that it could grow by 0.58%. Given that Adaptive Biotechnologies Corp. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Adaptive Biotechnologies Corp. is more attractive than Regeneron Pharmaceuticals, Inc..

Adaptive Biotechnologies Corp. has a beta of 2.201, which suggesting that the stock is 120.134% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.095%.

Adaptive Biotechnologies Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.45% to investors and pays a quarterly dividend of $0.88 per share. Adaptive Biotechnologies Corp. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Adaptive Biotechnologies Corp. quarterly revenues are $94M, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Adaptive Biotechnologies Corp.'s net income of $9.5M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Adaptive Biotechnologies Corp.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adaptive Biotechnologies Corp. is 10.10x versus 6.06x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals, Inc. has a net margin of 10.16% compared to Adaptive Biotechnologies Corp.'s net margin of 34.76%. Adaptive Biotechnologies Corp.'s return on equity of -39.8% beat Vertex Pharmaceuticals, Inc.'s return on equity of 22.13%.

Adaptive Biotechnologies Corp. has a consensus price target of $19.86, signalling upside risk potential of 18.55%. On the other hand Vertex Pharmaceuticals, Inc. has an analysts' consensus of $491.92 which suggests that it could grow by 6.25%. Given that Adaptive Biotechnologies Corp. has higher upside potential than Vertex Pharmaceuticals, Inc., analysts believe Adaptive Biotechnologies Corp. is more attractive than Vertex Pharmaceuticals, Inc..

Adaptive Biotechnologies Corp. has a beta of 2.201, which suggesting that the stock is 120.134% more volatile than S&P 500. In comparison Vertex Pharmaceuticals, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.249%.

Adaptive Biotechnologies Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adaptive Biotechnologies Corp. pays -- of its earnings as a dividend. Vertex Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Adaptive Biotechnologies Corp. quarterly revenues are $94M, which are smaller than Vertex Pharmaceuticals, Inc. quarterly revenues of $3.1B. Adaptive Biotechnologies Corp.'s net income of $9.5M is lower than Vertex Pharmaceuticals, Inc.'s net income of $1.1B. Notably, Adaptive Biotechnologies Corp.'s price-to-earnings ratio is -- while Vertex Pharmaceuticals, Inc.'s PE ratio is 32.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adaptive Biotechnologies Corp. is 10.10x versus 10.22x for Vertex Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Zymeworks, Inc. has a net margin of 10.16% compared to Adaptive Biotechnologies Corp.'s net margin of -70.99%. Adaptive Biotechnologies Corp.'s return on equity of -39.8% beat Zymeworks, Inc.'s return on equity of -18.82%.

Adaptive Biotechnologies Corp. has a consensus price target of $19.86, signalling upside risk potential of 18.55%. On the other hand Zymeworks, Inc. has an analysts' consensus of $35.54 which suggests that it could grow by 32.31%. Given that Zymeworks, Inc. has higher upside potential than Adaptive Biotechnologies Corp., analysts believe Zymeworks, Inc. is more attractive than Adaptive Biotechnologies Corp..

Adaptive Biotechnologies Corp. has a beta of 2.201, which suggesting that the stock is 120.134% more volatile than S&P 500. In comparison Zymeworks, Inc. has a beta of 1.269, suggesting its more volatile than the S&P 500 by 26.869%.

Adaptive Biotechnologies Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zymeworks, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adaptive Biotechnologies Corp. pays -- of its earnings as a dividend. Zymeworks, Inc. pays out -- of its earnings as a dividend.

Adaptive Biotechnologies Corp. quarterly revenues are $94M, which are larger than Zymeworks, Inc. quarterly revenues of $27.6M. Adaptive Biotechnologies Corp.'s net income of $9.5M is higher than Zymeworks, Inc.'s net income of -$19.6M. Notably, Adaptive Biotechnologies Corp.'s price-to-earnings ratio is -- while Zymeworks, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adaptive Biotechnologies Corp. is 10.10x versus 15.13x for Zymeworks, Inc.. Usually stocks with elevated PS ratios are considered overvalued.